ESR1

Overview

ESR1 (Estrogen Receptor 1), also known as estrogen receptor alpha (Estrogen Receptor Alpha (ERα)), is a nuclear receptor encoded by the ESR1 gene on chromosome 6q25.1. As a ligand-activated transcription factor it mediates the effects of estrogen by binding estrogen response elements in target gene promoters, regulating proliferation, differentiation and survival in breast, uterus, ovary, bone and liver. Estrogen binding drives a conformational change that promotes dimerization, coactivator recruitment and transcription of genes governing cell-cycle progression and apoptosis suppression; a membrane-associated pool also signals within minutes through the PI3K/Akt signaling pathway and JAK2/STAT3 signaling pathway, independently of transcription.

Roughly 70–80% of breast Cancers are estrogen receptor-positive, which makes the estrogen–ESR1 axis the principal target of endocrine therapy — though the drugs attack it at two different points. Aromatase inhibitors act on the enzyme CYP19A1 to cut estrogen synthesis, starving the receptor of ligand without touching it; selective estrogen receptor modulators such as tamoxifen bind the receptor itself and act as antagonists in breast tissue while remaining partial agonists elsewhere, which is why they carry an endometrial cancer risk; and selective estrogen receptor degraders bind and destroy it.

That distinction determines what happens at resistance. Under the selective pressure of estrogen deprivation, activating mutations in the ESR1 ligand-binding domain — Y537S and D538G most often — emerge in a substantial fraction of metastatic tumors and lock the receptor in an active conformation that no longer requires estrogen. Such tumors escape aromatase inhibitors entirely, since the problem is no longer ligand supply, while remaining partly susceptible to receptor-directed degraders; the mutations are detectable in circulating tumor DNA, and an oral degrader is approved specifically for this setting in breast cancer. Beyond oncology, ESR1 is implicated in reproductive disorders including polycystic ovary syndrome and endometriosis, and in metabolic and inflammatory conditions.

Recent Publications Summary

Recent studies have repeatedly implicated ESR1 as a key node in cancer-related and metabolic regulatory networks. In hepatocellular carcinoma, a network pharmacology and bioinformatics analysis of phytochemicals from Zanthoxylum nitidum identified ESR1 among five characteristic genes, and reported that ESR1 correlated with patient prognosis and showed epigenetic variation in methylation and copy number; the study also suggested involvement in tumour microenvironment regulation and HCC-related pathways such as the PPAR signalling pathway 42498300Jul. A separate network pharmacology study of the nutraceutical Vernolac likewise identified ESR1 as one of 14 hub nodes in a cancer-associated protein interaction network 42384725Jul. In acute liver injury, ESR1 was included among four hub genes emerging from an integrated network pharmacology and transcriptomic analysis of hepatoprotective monomers 42007886Apr.

ESR1 was also highlighted in studies of environmental exposures and breast cancer progression. In gestational diabetes research, ESR1 and SIRT1 were identified as critical regulatory hubs linking PFAS exposure to metabolic dysfunction, alongside pathway signals involving PPAR, AMPK, FoxO, and PI3K-Akt 42208379May. In breast cancer, a multi-omics study of di-(2-ethylhexyl) terephthalate (DOTP) found ESR1 among six high-affinity docking targets and reported that DOTP exposure promoted tumour cell proliferation with concentration-dependent upregulation of ESR1 protein levels 41780785Mar. Another breast cancer review emphasized that endocrine resistance in metastatic disease is often mediated by acquired ESR1 mutations that drive ligand-independent estrogen receptor activation and reduce sensitivity to standard antiestrogens 42413061Jul.

Therapeutic studies also linked ESR1 to endocrine-directed interventions. A review of emerging selective estrogen receptor degraders (SERDs) and other ER-targeted therapies noted that oral SERDs and related agents show enhanced anticancer activity, particularly in ESR1-mutant disease, and that combinations with CDK4/6 inhibitors and other targeted agents are advancing clinically 42413061Jul. In addition, the approval of vepdegestrant was highlighted as the first PROTAC drug to receive regulatory clearance, providing a new option for patients with ESR1-mutant advanced breast cancer after failure of standard hormone-based regimens 42137912May. In reproductive research, a traditional Chinese medicine combination of Guilu Erxian Glue and Wuzi Yanzong Pill was reported to attenuate granulosa cell apoptosis and improve cyclophosphamide-induced diminished ovarian reserve through the lncRNA NEAT1/miR-204-5p/ESR1 axis 41616885Jan.

What Changes, What Holds

1. ESR1 is emerging as a broader cancer and metabolic network node, but not a replacement mechanism
NEW DIRECTION Network-based studies extend ESR1 beyond its established endocrine role by placing it in hepatocellular carcinoma, acute liver injury, and metabolic regulatory circuits, including prognosis-linked epigenetic variation and pathway associations. That broadens the map of ESR1-linked biology without displacing the baseline account of ESR1 as a nuclear receptor central to estrogen signaling and breast cancer therapy. The evidence is largely computational and correlative, so these roles remain hypothesis-generating rather than settled 42498300Jul42007886Apr.

2. Environmental exposures may upregulate ESR1 and exploit its breast-cancer signaling axis
NEW DIRECTION DOTP-associated ESR1 protein increase and the PFAS-linked metabolic hub findings add an exposure biology layer that the Overview does not cover: ESR1 may be a downstream mediator of chemical perturbation in breast cancer progression and gestational diabetes-related dysfunction. This does not contradict ESR1’s established role in proliferation and endocrine responsiveness; it suggests external compounds can modulate that axis in disease-relevant ways. The breast-cancer result is preclinical, so causality and clinical relevance still need confirmation 41780785Mar42208379May.

3. ESR1-mutant disease is becoming a distinct therapeutic category
REINFORCES The new treatment-focused work sharpens, rather than revises, the baseline view that activating ESR1 mutations drive acquired endocrine resistance in advanced breast cancer. Oral SERDs, combination strategies, and vepdegestrant’s clearance all fit the established model of targeting mutant ESR1 to restore endocrine control. The main update is practical: ESR1 mutation status is increasingly actionable for therapy selection, but the underlying biology is confirmatory rather than new 42413061Jul42137912May.